Firstsource Solutions Limited (FSL) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Firstsource Solutions, an RP-Sanjiv Goenka Group business process management company serving BFS, Healthcare, CMT and Diverse Industries clients, heads into its Q2 FY27 print with a seven-quarter margin expansion streak and a 10%-13% constant currency growth guidance to defend. The print will speak to whether the healthcare BPaaS wind-down (a 1%-1.5% growth impact already absorbed into guidance) and payer-side recalibration dent the growth path, and whether EBIT margin — 12.4% in Q1 — keeps climbing toward the 12.25%-12.75% FY27 band.

Firstsource Solutions Limited Q2 Results Date and Time

The Board of Directors will meet on October 29, 2026, to consider audited standalone and consolidated results for the quarter and half year ended September 30, 2026 (Regulation 29, SEBI LODR).

An earnings conference call is scheduled for Thursday, October 29, 2026, at 5:30 p.m. IST, to discuss Q2/H1 FY27 performance for the quarter and half year ended September 30, 2026.

What to expect from Firstsource Solutions Limited's Q2 FY27 results

The central test for Q2 FY27 is consistency: Q1 constant currency growth of 12.3% against a reaffirmed FY27 band of 10%-13%, with management guiding that growth will be evenly distributed across the four quarters rather than back-ended. The known drag is company-specific and already absorbed — the healthcare BPaaS engagement wind-down, worth roughly 1%-1.5% of FY27 growth, which management called 'a very isolated, one-off instance' while holding guidance unchanged. Margin momentum enters the quarter at 12.4% EBIT after seven straight quarters of expansion (from 11% eight quarters ago), against a low base of 11.5% in Q2 FY26, with the rupee's roughly 1.3% depreciation against the dollar across the July-September window a modest tailwind given the USD 67.4% / GBP 30.3% revenue mix. On healthcare, management has characterised Medicare Advantage recalibration as 'a pacing effect, not a demand shift', and the CMS CY2027 rate update of 2.48% plus benefit trims land mostly in 2027 rather than this quarter. The deal engine is the other proof point: four large deals in Q1 made six consecutive quarters of 4-plus wins, with the highest ACV intake in four quarters and the best deal wins in five quarters against a pipeline the company called healthy and robust. The call will also be watched for any first quantification of AI-led pricing deflation, which management has not yet sized.

Key Things To Watch

FY27 guidance tracking: Management reaffirmed all FY27 guidance on August 6, 2026, even after absorbing the BPaaS wind-down.

• FY27 constant currency revenue growth — 10% to 13% — Q1 FY27 CC growth was 12.3%; watch whether H1 tracking and the absorbed 1%-1.5% BPaaS wind-down impact keep the full-year band intact
• FY27 EBIT margin — 12.25% to 12.75% — Q1 FY27 printed 12.4%, above the band's midpoint; watch for any revision or reiteration
• EBIT margin — 14% to 15% band over the next two to three years (per Q1 FY27 framing, tightened from '3 to 4 years'); check for any change in the stated timeline
• FY27 effective tax rate — 20% to 22%; growth phasing — evenly distributed across FY27 quarters, with H2 strength as new wins ramp

Healthcare BPaaS wind-down and payer momentum

• Recovery of the Rs. 35.67 Cr contract-termination outstanding provided in Q1 FY27 — any recovery, write-back, or further provision
• Whether the 'pacing, not demand' characterisation of Medicare Advantage recalibration holds, with CMS's 2.48% CY2027 rate update and benefit trims landing mostly in 2027
• Quantification of the BPaaS wind-down's Q2 revenue drag after Healthcare's (2)% QoQ in Q1 on program timing

Margin bridge and cost puts and takes

• Whether the expansion streak extends to eight quarters — Q2 FY26 base of 11.5% EBIT margin, with currency movement and salary hikes versus operational efficiency and productivity gains as the stated bridge items
• UK onshore-to-South Africa shift (UK headcount down ~40% over four quarters, South Africa up ~50%) — management could not quantify the revenue-deflation impact
• Any first quantification of AI-led pricing deflation, which management has not yet sized

Deal cadence and AI conversion

• Whether the six-quarter streak of 4+ large deals extends and ACV intake stays elevated after Q1's best-in-five-quarters deal wins
• Evidence that 'Intelligence That Operates'/Kairos converts into TCV, non-linear revenue share (upwards of 50% of business in non-linear constructs) and revenue per employee gains
• Headcount trajectory against TTM attrition of 27.5% (down 2.2 pp QoQ) after headcount rose ~670 QoQ to 36,875

Operating metric trajectory

• Vertical growth mix from Q1 FY27: BFS +14% YoY, Healthcare +11% YoY, CMT +6% YoY and +9% QoQ, Diverse +27% YoY; watch CMT normalisation as 'transitions complete and volumes normalize'
• Geography momentum: North America +8% YoY, Europe +18% YoY, Australia doubled YoY in Q1 FY27
• Net debt trajectory — FY26-end net debt of Rs. 16,287 Mn after acquisitions and dividend; watch funding of any further tuck-ins